Skip to main content

DCVMN Strengthens Global Vaccine Collaboration at the Vaccine Innovation Forum 2025

DCVMN at the Vaccine Innovation Forum 2025 strengthening global vaccine access! DCVMN International is committed to ensuring that vaccine manufacturers in developing countries have a strong voice in shaping the future of global health. As part of this mission, our CEO, Rajinder Suri, participated in the Vaccine Innovation Forum 2025 in Shanghai, China, engaging in critical discussions on vaccine equity, innovation, and accessibility.

๐Ÿ”น ๐—ฃ๐—น๐—ฒ๐—ป๐—ฎ๐—ฟ๐˜† ๐—ฃ๐—ฎ๐—ป๐—ฒ๐—น: ๐—š๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐—ฉ๐—ฎ๐—ฐ๐—ฐ๐—ถ๐—ป๐—ฒ ๐—˜๐—พ๐˜‚๐—ถ๐˜๐˜†
In the Plenary Panel chaired by Dr. Raman Rao, Rajinder Suri joined global leaders to address the challenges in vaccine distribution and access, emphasizing the need for sustainable solutions that empower vaccine manufacturers in developing countries in order to strengthen global health security.

๐Ÿ”น ๐——๐—–๐—ฉ๐— ๐—ก ๐—™๐—ผ๐—ฟ๐˜‚๐—บ
Co-chaired by Rajinder Suri and Andrew Wong from member company Walvax Biotechnology, the forum brought together experts from PATH, Gates Foundation, Biokangtai, SK bioscience, and SPbSRIVS FMBA of Russia to discuss key issues, including:
– Strengthening vaccine manufacturing in developing countries
– Innovations tailored for low-resource settings
– Chinaโ€™s vaccine development landscape
– Tech transfer strategies for sustainable production
– Lessons from Latin Americaโ€™s vaccine initiatives
– The future of global HPV vaccine introduction

The discussions reinforced the ๐—ฐ๐—ฟ๐—ถ๐˜๐—ถ๐—ฐ๐—ฎ๐—น ๐—ป๐—ฒ๐—ฒ๐—ฑ ๐—ณ๐—ผ๐—ฟ ๐—ฐ๐—ผ๐—น๐—น๐—ฎ๐—ฏ๐—ผ๐—ฟ๐—ฎ๐˜๐—ถ๐—ผ๐—ป, ๐˜๐—ฒ๐—ฐ๐—ต๐—ป๐—ผ๐—น๐—ผ๐—ด๐˜† ๐˜๐—ฟ๐—ฎ๐—ป๐˜€๐—ณ๐—ฒ๐—ฟ, ๐—ฎ๐—ป๐—ฑ ๐˜€๐˜‚๐˜€๐˜๐—ฎ๐—ถ๐—ป๐—ฎ๐—ฏ๐—น๐—ฒ ๐˜ƒ๐—ฎ๐—ฐ๐—ฐ๐—ถ๐—ป๐—ฒ ๐—บ๐—ฎ๐—ป๐˜‚๐—ณ๐—ฎ๐—ฐ๐˜๐˜‚๐—ฟ๐—ถ๐—ป๐—ด to ensure equitable access worldwide. A sincere thank you to all our member companies, partners, and global health leaders who contributed to these critical conversations.

Together, we continue to advance equitable and sustainable vaccine access for all!